Discussion  by unknown
procedures.14,15 Emerging minimally invasive diagnostic
modalities will continue to challenge established ap-
proaches. To remain at the forefront of the diagnosis, stag-
ing, and management of lung cancer, surgeons should
invest the time and effort necessary to evaluate new technol-
ogy firsthand.
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Dr S. Swisher (Houston, Tex). Endobronchial ultrasonography
is a novel minimally invasive technology that allows diagnosis and
staging of mediastinal nodes through ultrasound-guided fine-nee-
dle aspiration. Dr Gilbert and colleagues are to be commended
for rapidly incorporating this new technology into the thoracic sur-
geon’s armamentarium and reviewing their preliminary results. It is
critical to our profession that thoracic surgeons remain at the van-
guard in learning this technique and assessing its strengths and
weaknesses compared with other standard techniques, such as me-
diastinoscopy, so that as a profession, we remain included in the
process of evaluating and staging lung cancer in patients.
My first questions revolve around diagnostic accuracy. Seventy-
five patients were reviewed in this series for a variety of reasons,
including diagnosis of malignancy and staging of lung cancer.
The authors found that rapid on-site assessment was diagnosticThe Journal of Thoracic and Conly 69% of the time, whereas final cytologic evaluation was diag-
nostic 74% of the time. The authors could not identify any factors
that were associated with improved diagnostic accuracy, including
operator experience or number of lymph node stations sampled. In
most series the diagnostic yield is higher than what the authors re-
port here. How do the authors explain their diagnostic yield of
74%?
Most studies have also demonstrated that the number of aspira-
tions of each nodal station correlates with accuracy. How many
passes were performed in this study at each nodal station, and could
this have influenced diagnostic yield?
Lymph node size has also been found to correlate with diagnos-
tic yield in several studies. Did the authors evaluate lymph node
size with respect to the sampling accuracy, and did this correlate
with diagnostic yield?
Finally, of note, 56% of the patients in this study had only 1
nodal station sampled. Why did the authors not sample more lymph
nodes stations? Was it not possible in some of these patients?
Dr Gilbert. I will attempt to answer all of your pertinent ques-
tions in the sequence they were posed. The diagnostic yield of
EBUS can be influenced significantly by the definition of a ‘‘diag-
nostic sample’’ and the prevalence of cancer in the population stud-
ied. We have used stringent definitions of what is considered
‘‘diagnostic’’ when compared with other published series of
EBUS. For instance, specimens interpreted as ‘‘suspicious for ma-
lignancy’’ or ‘‘atypical cells present’’ were not considered diagnos-
tic because, in our opinion, clinical decisions cannot be safely based
on such results.
The setting of your EBUS review can be used as an example to
illustrate my second point regarding diagnostic yield. If a study of
EBUS is carried out in a large cancer center, it is possible that a sig-
nificant proportion of the patients will have mediastinal adenopathy
of malignant cause. The nature of the cancer center’s referral pat-
tern would likely bias the study population in that manner. When
using a highly specific diagnostic test, such as EBUS-TBNA, the
diagnostic yield will automatically appear better in study popula-
tions with higher cancer prevalence. This epidemiologic phenome-
non alone will result in improved diagnostic yield regardless of
other factors (eg, lymph node size, number of needle passes, oper-
ator experience, and cytology expertise). The prevalence of cancer
in our study was relatively low compared with other series, and this
probably had an impact on our diagnostic yield. The diagnostic per-
formance of EBUS at our institution is actually comparable to re-
sults previously published in the Journal of the American
Medical Association by Dr Wallace et al from the Mayo Clinic.
In the hands of these investigators, EBUS-TBNA alone had a lower
sensitivity, specificity, and positive predictive value and a higher
false-negative rate than what we have obtained in our initial expe-
rience. Because the prevalence of cancer in their study group and
ours was similar, the diagnostic performance parameters should
be comparable.
With regard to the number of needle passes per lymph nodes, we
did not look at this data specifically. We routinely use 3 passes per
lymph node unless a positive cancer diagnosis is obtained with
a lesser number of passes. In general, if the rapid on-site cytologic
evaluation remains nondiagnostic after 3 to 4 needle passes, we
move on to the next lymph node station to be sampled or perform
a mediastinoscopy when appropriate.ardiovascular Surgery c Volume 137, Number 2 417
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SWith regards to lymph node size, patients were stratified as hav-
ing lymph nodes smaller or equal to 1 cm in their shortest axis or
larger than 1 cm. There was no difference in diagnostic yield be-
tween those 2 subgroups.
You also asked why 56% of the patients did not have multi-
station sampling as is routinely done during mediastinoscopy.
Our study sample included a heterogenous group of patients
thought to be reflective of general thoracic surgery practice. For in-
stance, we evaluated patients with a suspected recurrent cancer in
a single abnormal mediastinal or hilar lymph node station on imag-
ing, patients who were eventually diagnosed with small cell lung
cancer, metastatic cancer, or sarcoidosis after the first station sam-
pled, and patients with N3 disease. These clinical situations do not
always require multiple stations to be sampled in order to obtain
a diagnosis and stage, and to devise a treatment plan. In patients
where the mediastinum is staged in preparation for lung resection,
our approach is to evaluate bilateral paratracheal and subcarinal sta-
tions beginning with the N3 lymph node stations.
Dr Swisher. My second question revolves around the impor-
tance of using EBUS and pathologic staging to assess PET-positive
mediastinal nodes. We are in an era similar to before when CT in-
crease in size of greater than 1 cm was taken by the oncologist to
mean positive nodes, often without pathology. Now we are doing
the same thing with new technology, and it’s critical that we can
pathologically evaluate this. EBUS may be an avenue to allow
pathologic confirmation. In the present series, diagnostic accuracy
was only 67%, with 29 of 43 PET-positive cases. In the 14 cases in
which EBUS was nondiagnostic, was the node in question visual-
ized and accessible by EBUS? Were these nodes in regions that
would have been accessible by mediastinoscopy, or were they in
the hilar or anteroposterior window regions?
Dr Gilbert. Four of these patients had a previous lung resection
for lung cancer. Two underwent mediastinoscopy which was neg-
ative and 1 had a percutaneous fine-needle aspiration of a right par-
atracheal node which was positive for recurrent cancer. The fourth
patient’s follow-up PET scan showed resolution of the mediastinal
FDG uptake and he was obsereved. Four additional patients had
abnormal lymph node stations not accessible by mediastinoscopy.
The remaining 6 patients had PET-positive mediastinal lymph
nodes. Three underwent mediastinoscopy and it was positive for
cancer in 2 and negative in 1. The latter patient had an EBUS-
TBNA which was suspicious for lymphoma. The fourth patient
had transbronchial biopsy of his lung mass which showed necrotiz-
ing granulomata. This type of biopsy was not considered an accept-
able reference standard for EBUS as stated in our methods. The fifth
patient had lung cancer and had previously received thoracic radio-
theraphy. He was deemed a non-surgical candidate and declined to418 The Journal of Thoracic and Cardiovascular Surhave more invasive diagnostic procedures performed. The last pa-
tient had a MRI scan for shoulder symptoms which revealed a scap-
ular metastasis. He did not require any further mediastinal workup.
Dr Patterson. Let me just interrupt. In the interest of time, can
we have minimal commentary and maximal short questions be-
cause we have a couple of other discussants who want to ask
some questions.
Dr Swisher. Thank you for bringing these preliminary results to
the forefront of our group.
Dr Gilbert. Thank you, Sir.
Dr R. Cerfolio (Birmingham, Ala). What was considered a pos-
itive PET? Did you use an absolute value of the node, ratio of the
node to the primary tumor?
Dr Gilbert. Given the retrospective study design, the radiology
reports were reviewed to determine whether or not a given site was
positive or negative on PET. Standard uptake values are not always
reported at our institution. From my discussions with nuclear med-
icine specialists and radiologists, a baseline level of FDG uptake is
usually established, using the liver parenchyma for instance, and
abnormal levels of FDG avidity are established in relationship to
that baseline in each patient.
Dr Cerfolio. Okay—not ideal, was it. My second question is
about the logistics and the politics. To keep everybody happy,
the surgeons, pulmonologists, and pulmonary fellows, how are
you doing it so the pulmonary fellows can come through to keep
the pulmonologists happy, because they also control our volume,
and the cardiothoracic fellows; how are you doing it at your insti-
tution to keep everybody happy?
Dr Gilbert. For those who wish to use the EBUS scopes ac-
quired by the operating room, we have established basic credential-
ing requirements, which include completion of an off-site EBUS
course and at least 5 on-site proctored cases. In our group, there
is a pulmonologist who performs and teaches the procedure rou-
tinely. I believe that people who share a common interest in the di-
agnosis and treatment of lung cancer and mediastinal disease should
consider learning the technique, regardless of their specialty.
Dr A. Vaporciyan (Houston, Tex). We have struggled with how
many proctored EBUSs are required before one is considered
trained in this. Obviously everybody has different definitions.
Where did you come up with 5 proctored EBUSs to consider your-
self trained in it? Was it from literature or your experience?
Dr Gilbert. It is an institution-specific policy which was estab-
lished after discussion with the departmental chair. The literature
suggest that 30-50 supervised procedures may be needed for pulmo-
nologists to establish proficiency. This number may be lower for
thoracic surgeons given their clinical training and operative experi-
ence with lung cancer and mediastinal diseases.gery c February 2009
